TY - JOUR
T1 - Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab
T2 - A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
AU - Dempster, David W.
AU - Zhou, Hua
AU - Recker, Robert R.
AU - Brown, Jacques P.
AU - Recknor, Christopher P.
AU - Lewiecki, E. Michael
AU - Miller, Paul D.
AU - Rao, Sudhaker D.
AU - Kendler, David L.
AU - Lindsay, Robert
AU - Krege, John H.
AU - Alam, Jahangir
AU - Taylor, Kathleen A.
AU - Melby, Thomas E.
AU - Ruff, Valerie A.
N1 - Funding Information:
We thank the study investigators, site personnel, and patients and their families. This work was sponsored by Eli Lilly and Company. Trial registration: ClinicalTrials.gov: NCT01753856.
Funding Information:
We thank the study investigators, site personnel, and patients and their families. This work was sponsored by Eli Lilly and Company. Trial registration: ClinicalTrials.gov: NCT01753856. Authors? roles: Study design: JHK. Study conduct: VAR. Data collection: HZ. Data analysis: HZ and JA. Data interpretation: DWD, HZ, VAR, and TEM. Drafting manuscript: VAR, DWD, and TEM. Revising manuscript content: DWD, HZ, RRR, JPB, CPR, EML, PDM, SDR, DLK, RL, JHK, JA, KAT, TEM, and VAR. Approving final version of manuscript: DWD, HZ, RRR, JPB, CPR, EML, PDM, SDR, DLK, RL, JHK, JA, KAT, TEM, and VAR. JA takes responsibility for the integrity of the data analysis.
Funding Information:
DWD has received research grants from Eli Lilly and Company; is a consultant and is on advisory boards for Eli Lilly and Company, Amgen, and Merck; is on speakers’ bureaus at Eli Lilly and Company and Amgen; and has received honoraria from Eli Lilly and Company, Amgen, Radius Health, and Merck. RRR has received institutional grant/research support, has been a consultant and served on advisory boards for Merck, Eli Lilly and Company, Amgen, Radius Health, and Novartis. JPB receives research grants from Amgen and Eli Lilly and Company; serves as a consultant for Amgen, Eli Lilly and Company, and Merck; and is a speaker for Amgen and Eli Lilly and Company. CPR has received grant/research support from Amgen, Merck, Eli Lilly and Company, and Novartis, and has served on scientific advisory boards for Amgen, Merck, Eli Lilly and Company, NPS, and Novartis and receives honorarium and travel expenses for advisory boards. EML has received institutional grant/research support from Amgen, Merck, and Eli Lilly and Company; has served on scientific advisory boards for Amgen, Merck, Eli Lilly and Company, Radius Health, AgNovos Healthcare, Alexion, NPS, and AbbVie; and receives honorarium and travel expenses for advisory boards. PDM serves on scientific advisory boards for Alexion, Amgen, AgNovos, Eli Lilly and Company, Merck, Radius Pharma, and Roche; and receives research grants from Amgen, Boehringer Ingelheim, Immunodiagnostics, Eli Lilly and Company, Merck, Merck Serrano, Novartis, Novo Nordisk, Radius Pharma, Roche Diagnostics, and Takeda. SDR receives research grants from Eli Lilly and Company and NIH/NIAMS. DLK receives research grants, consultancies, and/or honoraria from Amgen, Eli Lilly and Company, Pfizer, GSK, Astra Zeneca, and Astellas. RL is a speaker for Eli Lilly and Company. JHK, JA, KAT, and VAR are employees of Eli Lilly and Company and own stock. TEM is an employee of INC Research/inVentiv Health, working under contract to Eli Lilly and Company. HZ has nothing to declare.
Publisher Copyright:
© 2017 American Society for Bone and Mineral Research
PY - 2018/2
Y1 - 2018/2
N2 - There has been renewed interest of late in the role of modeling-based formation (MBF) during osteoporosis therapy. Here we describe early effects of an established anabolic (teriparatide) versus antiresorptive (denosumab) agent on remodeling-based formation (RBF), MBF, and overflow MBF (oMBF) in human transiliac bone biopsies. Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites. Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months. Sites of bone formation were designated as MBF if the underlying cement line was smooth, RBF if scalloped, and oMBF if formed over smooth cement lines adjacent to scalloped reversal lines. At baseline, mean RBF/bone surface (BS), MBF/BS, and oMBF/BS were similar between the teriparatide and denosumab groups in each bone envelope assessed (cancellous, endocortical, periosteal). All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001). In contrast, all types of formation were decreased or not significantly changed with denosumab, except MBF/BS in the cancellous envelope, which increased 2.5-fold (difference p = 0.048). These data highlight mechanistic differences between these agents: all 3 types of bone formation increased significantly with teriparatide, whereas formation was predominantly decreased or not significantly changed with denosumab, except for a slight increase in MBF/BS in the cancellous envelope.
AB - There has been renewed interest of late in the role of modeling-based formation (MBF) during osteoporosis therapy. Here we describe early effects of an established anabolic (teriparatide) versus antiresorptive (denosumab) agent on remodeling-based formation (RBF), MBF, and overflow MBF (oMBF) in human transiliac bone biopsies. Postmenopausal women with osteoporosis received subcutaneous teriparatide (n = 33, 20 μg/d) or denosumab (n = 36, 60 mg once/6 months), open-label for 6 months at 7 US and Canadian sites. Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months. Sites of bone formation were designated as MBF if the underlying cement line was smooth, RBF if scalloped, and oMBF if formed over smooth cement lines adjacent to scalloped reversal lines. At baseline, mean RBF/bone surface (BS), MBF/BS, and oMBF/BS were similar between the teriparatide and denosumab groups in each bone envelope assessed (cancellous, endocortical, periosteal). All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p < 0.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p < 0.001). In contrast, all types of formation were decreased or not significantly changed with denosumab, except MBF/BS in the cancellous envelope, which increased 2.5-fold (difference p = 0.048). These data highlight mechanistic differences between these agents: all 3 types of bone formation increased significantly with teriparatide, whereas formation was predominantly decreased or not significantly changed with denosumab, except for a slight increase in MBF/BS in the cancellous envelope.
UR - http://www.scopus.com/inward/record.url?scp=85034073268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85034073268&partnerID=8YFLogxK
U2 - 10.1002/jbmr.3309
DO - 10.1002/jbmr.3309
M3 - Article
C2 - 29024120
AN - SCOPUS:85034073268
VL - 33
SP - 298
EP - 306
JO - Journal of Bone and Mineral Research
JF - Journal of Bone and Mineral Research
SN - 0884-0431
IS - 2
ER -